Day One: Tuesday March 7, 2017

REGISTRATION & COFFEE

8:00

Introduction and Summary

8:15

Antibody Drug Conjugates for Breast Cancer

8:30

 

PCA062: An ADC for the Treatment of P-Cadherin Positive Solid Tumors

 

Tony d'Alessio

Research Investigator, Oncology Biotherapeutics

 

Novartis Institutes for BioMedical Research

9:00

XMT-1522: Efforts to Simultaneously Increase Efficacy and Tolerability to Benefit a Larger Her-2 Patient Population

Timothy Lowinger
Chief Scientific Officer

 

Mersana

9:30

9:45

10:00

Discovery of a Novel ADC in Breast and Ovarian Cancer

Marc Hyer

Senior Scientist, Biotherapeutics

 

Takeda

MEDI4276: A Biparatopic ADC Targeting HER2 Positive Cancers

 

Frank Comer

Scientist II

 

MedImmune

Challenges in ADC Manufacturing: From Conjugation to Fill-Finish

 

Giorgio Salciarini

Technical Business Development Manager

 

BSP Pharmaceuticals

MORNING REFRESHMENTS & SPEED NETWORKING

10:30

11:00

gpNMB: an important target for the ADC Glembatumumab vedotin in TNBC

 

 

Christopher Turner

VP Clinical Science

 

Celldex Therapeutics

11:30

Targeting Low HER2 Expressing Tumors with Bi-Specific Antibodies and Bi-Specific ADCs

 

Kevin Hamblett

Associate Director, ADC Development

Zymeworks

12:00

OMTX705: A Tumor microenvironment-targeted ADC to treat triple negative breast cancer

 

Myriam Fabre

R&D Director

 

Oncomatryx

12:30

Platform technology enables safer and more effective ADC product candidates in multiple breast cancer models

 

Floris van Delft

Chief Scientific Officer

 

SynAffix

12:45

Efficacy and Safety of Anti-Trop-2 ADC, Sacituzumab Govitecan (IMMU 132), in Heavily Pretreated Patients with Metastatic Triple-Negative Breast Cancer

Boyd Mudenda
Associate Vice President
Immunomedics

LUNCH & NETWORKING

1:15

Immunotherapies in Breast Cancer

1:45

PD-1 inhibition for breast cancer treatment

 

 

Vassiliki Karantza

Senior Director, Clinical Research Oncology

 

Merck

2:15

Design of rational immunotherapy combinations in Breast Cancer

 

 

Carol O'Hear

Associate Medical Director, Breast Cancer Immunotherapy Combination Group

 

Genentech

2:45

Margetuximab: ADCC enhancing anti-HER2 antibody


Naimish Pandya

Senior Director, Clinical Research & Development

 

 

MacroGenics

3:15

Biomarker driven immunotherapy in breast cancer



Beth Trehu

Chief Medical Officer

 

Jounce Therapeutics

3:45

An active immunotherapy combined with first-line weekly paclitaxel in metastatic breast cancer: first results of IMP321 (LAG-3Ig) as an antigen presenting cell activator in the AIPAC phase IIb trial.

 

Frederic Triebel

Chief Scientific Officer

Prima Biomed

AFTERNOON REFRESHMENTS & NETWORKING

4:15

Cancer Vaccines

4:30


Title TBA (Neuvax: A Breast Cancer Vaccine)

 

Michael Schwartz

President & Chief Executive Officer

Galena Biopharma

5:00


DNA vaccine design and therapeutics in breast cancer

 

Ildiko Csiki

Vice President Clinical Development Oncology

Inovio Pharmaceuticals

SUMMARY & CLOSE OF DAY ONE

5:30

VIEW NEXT DAY

DOWNLOAD EVENT GUIDE

Complete the form below to download the PDF

NEO SYNTH International House, 24 Holborn Viaduct, London EC1A 2BN

contact@neo-synth.com

(+1) 617.500.5172

Submitting Form...

The server encountered an error.

Request received. Please allow some time for processing - You will receive a manual response within a few hours.

Your details will not be shared with a third party

Copyright © 2016 | All content produced by: neo-synth ltd.

Registration

PCA062: An ADC for the Treatment of P-Cadherin Positive Solid Tumors

 

Tony d'Alessio

Research Investigator, Oncology Biotherapeutics

 

Novartis Institutes for BioMedical Research

XMT-1522: Efforts to Simultaneously Increase Efficacy and Tolerability to Benefit a Larger Her-2 Patient Population

Timothy Lowinger
Chief Scientific Officer

Mersana

Discovery of a Novel ADC in Breast and Ovarian Cancer

Marc Hyer, Senior Scientist, Biotherapeutics, Takeda

MEDI4276: A Biparatopic ADC Targeting HER2 Positive Cancers

 

Frank Comer, Scientist II

MedImmune

Conjugation & Fill/Finish at the Same Site, an Innovative Approach to the Supply of ADCs

 

Giorgio Salciarini

Technical Business Development Manager

 

BSP Pharmaceuticals

Speed Networking

gpNMB: an important target for the ADC Glembatumumab vedotin in TNBC

 

 

Christopher Turner

VP Clinical Science

Celldex Therapeutics

Targeting Low HER2 Expressing Tumors with Bi-Specific Antibodies and Bi-Specific ADCs

 

Kevin Hamblett

Associate Director, ADC Development

Zymeworks

OMTX705: A Tumor microenvironment-targeted ADC to treat triple negative breast cancer

 

Myriam Fabre

R&D Director

 

Oncomatryx

Platform technology enables safer and more effective ADC product candidates in multiple breast cancer models

Floris van Delft,

CSO,

SynAffix

Efficacy and Safety of Anti-Trop-2 ADC, Sacituzumab Govitecan (IMMU 132), in Heavily Pretreated Patients with Metastatic Triple-Negative Breast Cancer
Boyd Mudenda
Associate Vice President


Immunomedics

Lunch

Immunotherapies

PD-1 inhibition for breast cancer treatment

 

 

Vassiliki Karantza

Senior Director, Clinical Research Oncology

 

Merck

Design of rational immunotherapy combinations in Breast Cancer

 

 

Carol O'Hear

Associate Medical Director, Breast Cancer Immunotherapy Combination Group

 

Genentech

Margetuximab: ADCC enhancing anti-HER2 antibody

Naimish Pandya

Senior Director, Clinical Research & Development

MacroGenics

Biomarker driven immunotherapy in breast cancer



Beth Trehu

Chief Medical Officer

 

Jounce Therapeutics

An active immunotherapy combined with first-line weekly paclitaxel in metastatic breast cancer:

 

Frederic Triebel

Chief Scientific Officer

Prima Biomed

Coffee Break

Cancer Vaccines


Title TBA (Neuvax: A Breast Cancer Vaccine)

 

Michael Schwartz

President & Chief Executive Officer

Galena Biopharma


DNA vaccine design and therapeutics in breast cancer

 

Ildiko Csiki

Vice President Clinical Development Oncology

Inovio Pharmaceuticals

End of Day 1

DOWNLOAD GUIDE